Boston Scientific Corporation $BSX Stock: Mawer Investment Management Ltd. Increases Stake

Mawer Investment Management Ltd. lifted its holdings in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 70.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 904,543 shares of the medical equipment provider’s stock after purchasing an additional 374,010 shares during the quarter. Mawer Investment Management Ltd. owned 0.06% of Boston Scientific worth $39,483,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of BSX. BlackRock Inc. bought a new stake in Boston Scientific during the 2nd quarter worth approximately $5,534,781,000. Primecap Management Co. CA acquired a new stake in Boston Scientific during the 2nd quarter worth approximately $2,156,233,000. Janus Henderson Group PLC lifted its stake in Boston Scientific by 31.0% in the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock valued at $1,035,202,000 after buying an additional 3,907,981 shares in the last quarter. Amundi lifted its stake in Boston Scientific by 13.8% in the first quarter. Amundi now owns 14,122,913 shares of the medical equipment provider’s stock valued at $886,213,000 after buying an additional 1,707,754 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in shares of Boston Scientific by 25.9% in the first quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock valued at $871,702,000 after buying an additional 2,856,040 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.3%

Shares of NYSE BSX traded up $0.13 during midday trading on Friday, reaching $44.33. The company’s stock had a trading volume of 9,698,273 shares, compared to its average volume of 20,222,538. The company has a current ratio of 1.36, a quick ratio of 0.81 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a fifty-two week low of $39.57 and a fifty-two week high of $104.61. The stock has a market capitalization of $64.25 billion, a price-to-earnings ratio of 18.78, a PEG ratio of 1.31 and a beta of 0.60. The stock has a 50 day simple moving average of $44.00 and a 200-day simple moving average of $54.50.

Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting analysts’ consensus estimates of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The business had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the previous year, the firm posted $0.75 earnings per share. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. Equities research analysts predict that Boston Scientific Corporation will post 3.17 earnings per share for the current year.

Analyst Upgrades and Downgrades

BSX has been the subject of several research reports. Royal Bank Of Canada lowered their price objective on shares of Boston Scientific from $70.00 to $52.00 and set an “outperform” rating for the company in a research report on Thursday, October 29th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Boston Scientific in a research report on Friday, October 2nd. Robert W. Baird upped their target price on shares of Boston Scientific from $50.00 to $51.00 and gave the stock an “outperform” rating in a research note on Thursday, October 29th. Piper Sandler reduced their target price on shares of Boston Scientific from $65.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, July 29th. Finally, Jefferies Financial Group cut Boston Scientific from a “buy” rating to a “hold” rating and lowered their target price for the stock from $60.00 to $46.00 in a report on Wednesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $61.43.

Read Our Latest Research Report on BSX

Boston Scientific Company Profile

(Free Report)

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

See Also

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.